Scientific Abstracts 1289 a significant difference was found between the other groups (p<0.05). IHC with YKL-40 revealed staining of the vessels in the superficial dermis in SSc and normal skin remained unstained. The ROC curve for PAH showed an AUC=0.959, and the most valid cut-off levels of Background: Hypo or amyopathic dermatomyositis (DM) represent about 20% of the classic DM. Melanoma differentiation-associated gene 5 antibody or anti-MDA5 antibody, formerly known as anti-CADM140 antibody, has been reported in the last decade. This antibody is detected in more than 50% of patients with hypo or amyopathic DM and it has specific features such as the presence of ulcerative vascular lesions and rapid progression of the interstitial lung disease. Objectives: To report anti-MDA5 positive DM cases diagnosed at a university county hospital, between 2012 and 2016. Methods: Design: Retrospective descriptive study. Location: University county hospital. Reference area: ?350.000 inhabitants. Clinical manifestations, analytical results, diagnostic approach, treatment administered and follow-up have been exposed. Results: We report four anti-MDA5 positive DM with a mean age at diagnosis of 54 years (35-77). Caucasian origin in 2 men and Maghreb origin in 2 women. They had no relevant medical history neither neoproliferative process was detected. ANA were negative and CK values were normal in all the cases. Nailfold capillaroscopy was characteristic of DM pattern. Case B did not present cutaneous manifestations and he was diagnosed as anti-MDA5 DM after his death. Discussion: B and C cases showed abnormal heart rhythm that could be related to myocardial involvement, as suggested in a recent publication of anti-MDA5 DM (1). In case C, sinus tachycardia was resolved with the clinical response to treatment. In the literature reviewed, anti-MDA5 positive DM has been reported as a dermatopulmonary syndrome, but probably the clinical profile of these patients remains to be defined. In our cases, one of them did not present skin lesions and another case did not develop pulmonary involvement 18 months after the diagnosis. Conclusions: Keep in mind anti-MDA5 antibody in patients with cutaneous manifestations of DM with vasculopathy lesions, minimal or absent muscular disease, heart rhythm abnormalities not explained by other causes and/or rapidly progressive pulmonary involvement. Anti-MDA5 positive DM may have a poor response to treatment and fatal outcome. It remains to be seen if early diagnosis could improve the life expectancy of these patients.
a significant difference was found between the other groups (p<0.05). IHC with YKL-40 revealed staining of the vessels in the superficial dermis in SSc and normal skin remained unstained. The ROC curve for PAH showed an AUC=0.959, and the most valid cut-off levels of YKL-40 age percentile was 85.2 (sensitivity 86.7% and specificity 92.8%). Conclusions: Our report is the first report of IHC with 
Results:
We report four anti-MDA5 positive DM with a mean age at diagnosis of 54 years (35-77). Caucasian origin in 2 men and Maghreb origin in 2 women. They had no relevant medical history neither neoproliferative process was detected. ANA were negative and CK values were normal in all the cases. Nailfold capillaroscopy was characteristic of DM pattern. Case B did not present cutaneous manifestations and he was diagnosed as anti-MDA5 DM after his death. Discussion: B and C cases showed abnormal heart rhythm that could be related to myocardial involvement, as suggested in a recent publication of anti-MDA5 DM (1). In case C, sinus tachycardia was resolved with the clinical response to treatment. In the literature reviewed, anti-MDA5 positive DM has been reported as a dermatopulmonary syndrome, but probably the clinical profile of these patients remains to be defined. In our cases, one of them did not present skin lesions and another case did not develop pulmonary involvement 18 months after the diagnosis. Conclusions: Keep in mind anti-MDA5 antibody in patients with cutaneous manifestations of DM with vasculopathy lesions, minimal or absent muscular disease, heart rhythm abnormalities not explained by other causes and/or rapidly progressive pulmonary involvement. Anti-MDA5 positive DM may have a poor response to treatment and fatal outcome. It remains to be seen if early diagnosis could improve the life expectancy of these patients. Background: A higher prevalence of Pulmonary Hypertension (HP) has been described in patients with Systemic Sclerosis (ES) diagnosis, so this fact significantly overshadows the prognosis, since it leads to the failure of the right ventricle (RV). In this context, it could be very useful to identify ES patients who are at greater risk of developing PH in the future to make an early diagnosis of this complication, and prescribing an early theraphy to improve their prognosis. Objectives: The purpose of this study is to investigate if certain fibrosis, inflammation and vasculopathy biomarkers could be associated to early functional changes in RV, assessed by echocardiography and cardiac nuclear magnetic resonance (MRI) in ES patients. Methods: A cross-sectional study was performed on a cohort of ES patients diagnosed according to the LeRoy modified criteria, who were being following-up in the Systemic Autoimmune Diseases Unit of the Internal Medicine Service of La Paz Universitary Hospital. Serum levels of inflammation (IL-13, IL-6, TNF alpha), vasculopathy (VEGF), fibrosis biological markers (endoglin, PDRFR, TGFB1, TGFB2, TGFB3) and cardiac biomarkers (NT-proBNP, High sensitivity T troponin) were determinated as well as hemodynamic and cardiac morphological variables, were mesured by transthoracic echocardiography (systolic and diastolic eccentricity index, E/E' ratio, E/A, pulmonary artery systolic pressure, RV thickness) and cardiac MRI (Mean pulmonary artery velocity). We investigated how many patients had these markers elevated and how many of them had hemodynamic and morphological cardiac alterated measurements. Results: Twenty patients with a diagnosis of ES (18 females/2 males) aged between 41 and 77 years, with a mean of 56 years, were included. A control group of 9 patients with similar demographic characteristics was included. ES subjets had higher levels of PDGFR (fibrosis marke) compared to the control group. In addition, in the group of ES patients, two statistically significant associations were observed: troponin T levels (hs-cTnT), endoglin and TGFB2 had higher leves in pacients with a systolic eccentricity index >1; a negative correlation was evidenciated between levels of NT-proBNP and the mean pulmonary artery velocity measurement (VELAP).
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